The redox state of cytochrome C modulates resistance to methotrexate in human MCF7 breast cancer cells

dc.contributor.authorBarros, Susana Raquel Costa
dc.contributor.authorMencía Trinchant, Núria
dc.contributor.authorRodríguez Gallego, Laura
dc.contributor.authorOleaga Sancho, Carlota
dc.contributor.authorSantos, Conceição
dc.contributor.authorNoé Mata, Verónica
dc.contributor.authorCiudad i Gómez, Carlos Julián
dc.date.accessioned2014-02-13T16:07:18Z
dc.date.available2014-02-13T16:07:18Z
dc.date.issued2013-05-13
dc.date.updated2014-02-13T16:07:18Z
dc.description.abstractBackground: Methotrexate is a chemotherapeutic agent used to treat a variety of cancers. However, the occurrence of resistance limits its effectiveness. Cytochrome c in its reduced state is less capable of triggering the apoptotic cascade. Thus, we set up to study the relationship among redox state of cytochrome c, apoptosis and the development of resistance to methotrexate in MCF7 human breast cancer cells. Results: Cell incubation with cytochrome c-reducing agents, such as tetramethylphenylenediamine, ascorbate or reduced glutathione, decreased the mortality and apoptosis triggered by methotrexate. Conversely, depletion of glutathione increased the apoptotic action of methotrexate, showing an involvement of cytochrome c redox state in methotrexateinduced apoptosis. Methotrexate-resistant MCF7 cells showed increased levels of endogenous reduced glutathione and a higher capability to reduce exogenous cytochrome c. Using functional genomics we detected the overexpression of GSTM1 and GSTM4 in methotrexate-resistant MCF7 breast cancer cells, and determined that methotrexate was susceptible of glutathionylation by GSTs. The inhibition of these GSTM isoforms caused an increase in methotrexate cytotoxicity in sensitive and resistant cells. Conclusions: We conclude that overexpression of specific GSTMs, GSTM1 and GSTM4, together with increased endogenous reduced glutathione levels help to maintain a more reduced state of cytochrome c which, in turn, would decrease apoptosis, thus contributing to methotrexate resistance in human MCF7 breast cancer cells.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec628750
dc.identifier.issn1932-6203
dc.identifier.pmid23675469
dc.identifier.urihttps://hdl.handle.net/2445/49868
dc.language.isoeng
dc.publisherPublic Library of Science (PLoS)
dc.relation.isformatofReproducció del document publicat a: http://dx.doi.org/10.1371/journal.pone.0063276
dc.relation.ispartofPLoS One, 2013, vol. 8, num. 5, p. e63276
dc.relation.urihttp://dx.doi.org/10.1371/journal.pone.0063276
dc.rightscc-by (c) Barros, Susana et al., 2013
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es
dc.sourceArticles publicats en revistes (Bioquímica i Biomedicina Molecular)
dc.subject.classificationMetotrexat
dc.subject.classificationCàncer de mama
dc.subject.classificationQuimioteràpia del càncer
dc.subject.classificationCèl·lules canceroses
dc.subject.classificationResistència als medicaments
dc.subject.classificationApoptosi
dc.subject.otherMethotrexate
dc.subject.otherBreast cancer
dc.subject.otherCancer chemotherapy
dc.subject.otherCancer cells
dc.subject.otherDrug resistance
dc.subject.otherApoptosis
dc.titleThe redox state of cytochrome C modulates resistance to methotrexate in human MCF7 breast cancer cells
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
628750.pdf
Mida:
954.28 KB
Format:
Adobe Portable Document Format